Vasculitis & polymyalgia rheumatica
Dupilumab for refractory chronic rhinosinusitis in eosinophilic granulomatosis with polyangiitis
Authors' conclusion
Dupilumab is an effective treatment option for severe and refractory ENT manifestations in EGPA, as it improves symptoms, reduces inflammation, and leads to better a quality of life.
Study context
- Population
- Eosinophilic granulomatosis with polyangiitis (EGPA) patients with refractory chronic rhinosinusitis with nasal polyps (CRSwNP), in prolonged remission of vasculitis manifestations, treated with dupilumab 2021–2023
- Participants
- 9 patients
- Outcome
- Complete response (BVAS = 0 and prednisone dose ≤4 mg/day)
Main finding
As reported in the abstract
Complete response (BVAS = 0 and prednisone ≤4 mg/day) · 3 months
Complete response after 3 months
55.6%
Observational data: associations, not effects.
Further findings
Complete response (BVAS = 0 and prednisone ≤4 mg/day) · 12 months
- Complete response at 12 months
- 83.3%
Nasal symptoms and patient-reported outcome measures (PROMs) · 12 months
- Improved significantly, with sustained efficacy over 12 months
Quality of life (AAV-PRO score)
- Improvement in quality of life, with a significant reduction in the AAV-PRO score
Nasal cytology
- Reductions in eosinophils and neutrophils counts
Safety
| Outcome | Values |
|---|---|
| Adverse events | Dupilumab 44.4% |
- Adverse events — Hypereosinophilia leading to dupilumab discontinuation
- 2
Original publication
Dupilumab for refractory chronic rhinosinusitis in eosinophilic granulomatosis with polyangiitis. Rheumatology (Oxford). Published 16 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →